Royalty Pharma plc (NASDAQ:RPRX) Receives $41.67 Consensus Price Target from Brokerages

Royalty Pharma plc (NASDAQ:RPRX) has been given a consensus recommendation of “Moderate Buy” by the six research firms that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12 month price target among brokers that have covered the stock in the last year is $41.67.

RPRX has been the topic of a number of research analyst reports. StockNews.com cut shares of Royalty Pharma from a “buy” rating to a “hold” rating in a research report on Monday. The Goldman Sachs Group raised their price objective on Royalty Pharma from $50.00 to $51.00 and gave the company a “buy” rating in a research note on Wednesday, August 14th. Morgan Stanley upped their target price on Royalty Pharma from $48.00 to $51.00 and gave the stock an “overweight” rating in a research report on Thursday, July 11th. Finally, Citigroup reduced their price target on shares of Royalty Pharma from $60.00 to $40.00 and set a “buy” rating for the company in a research report on Friday, October 25th.

Royalty Pharma Trading Down 0.7 %

RPRX opened at $27.00 on Tuesday. The company has a debt-to-equity ratio of 0.78, a current ratio of 9.35 and a quick ratio of 9.35. Royalty Pharma has a fifty-two week low of $25.20 and a fifty-two week high of $31.66. The company’s 50 day moving average price is $27.99 and its two-hundred day moving average price is $27.57. The firm has a market capitalization of $16.13 billion, a price-to-earnings ratio of 20.15, a PEG ratio of 3.97 and a beta of 0.46.

Royalty Pharma (NASDAQ:RPRX) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $0.96 EPS for the quarter, topping analysts’ consensus estimates of $0.95 by $0.01. Royalty Pharma had a return on equity of 23.61% and a net margin of 30.08%. The company had revenue of $537.00 million for the quarter, compared to analyst estimates of $600.83 million. During the same period in the previous year, the firm earned $0.85 earnings per share. As a group, research analysts predict that Royalty Pharma will post 4.05 earnings per share for the current year.

Royalty Pharma Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be given a $0.21 dividend. The ex-dividend date of this dividend is Friday, November 15th. This represents a $0.84 dividend on an annualized basis and a yield of 3.11%. Royalty Pharma’s payout ratio is 62.69%.

Institutional Trading of Royalty Pharma

Hedge funds have recently added to or reduced their stakes in the business. Xponance Inc. grew its holdings in Royalty Pharma by 1.9% in the 2nd quarter. Xponance Inc. now owns 31,704 shares of the biopharmaceutical company’s stock worth $836,000 after acquiring an additional 606 shares during the last quarter. EverSource Wealth Advisors LLC grew its stake in shares of Royalty Pharma by 32.1% in the second quarter. EverSource Wealth Advisors LLC now owns 2,698 shares of the biopharmaceutical company’s stock worth $76,000 after purchasing an additional 655 shares during the last quarter. Values First Advisors Inc. increased its holdings in Royalty Pharma by 7.6% during the 3rd quarter. Values First Advisors Inc. now owns 10,412 shares of the biopharmaceutical company’s stock valued at $295,000 after purchasing an additional 738 shares during the period. Phillips Wealth Planners LLC raised its position in Royalty Pharma by 10.2% during the 3rd quarter. Phillips Wealth Planners LLC now owns 8,733 shares of the biopharmaceutical company’s stock valued at $246,000 after purchasing an additional 808 shares during the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. lifted its holdings in Royalty Pharma by 10.8% in the 1st quarter. Tokio Marine Asset Management Co. Ltd. now owns 9,097 shares of the biopharmaceutical company’s stock worth $276,000 after buying an additional 887 shares during the period. 54.35% of the stock is owned by institutional investors.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.